Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors

被引：0
|
作者：
Lin, C-C. [1 ]
Schneider, R. [2 ]
Gutierrez, M. [3 ]
Shen, L. [4 ]
Chung, K. [5 ]
Doroshow, D. B. [6 ]
Gao, B. [7 ,8 ]
Millward, M. [9 ]
Hsieh, C-Y. [10 ]
Xu, C. [10 ]
Cai, S. X. [10 ]
Tian, Y. E. [10 ]
Liu, L. [10 ]
Shen, C. [10 ]
Tan, Y. [10 ]
He, Y. [10 ]
Zhang, C. [10 ]
Li, L. [11 ]
Ma, M. [10 ]
Xu, L. [10 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Mary Crowley Canc Res, Dept Med Oncol, Dallas, TX USA
[3] Hackensack Univ, Dept Med Oncol, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[4] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China
[5] Prisma Hlth Syst Upstate, Clin Res, Inst Translat Oncol Res, Greenville, SC USA
[6] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA
[7] Blacktown Hosp, Haematol & Canc Care Ctr, Blacktown, NSW, Australia
[8] Univ Sydney, Blacktown, NSW, Australia
[9] Linear Clin Res, Oncol, Perth, WA, Australia
[10] IMPACT Therapeut Inc Shanghai, Clin Dev, Shanghai, Peoples R China
[11] IQVIA RDS Shanghai Co Ltd, Beijing Branch, Med, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.699
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
632P
引用
收藏
页码：S503 / S504
页数：2
相关论文
共 50 条
  • [41] First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors
    Yap, Timothy A.
    Tolcher, Anthony W.
    Plummer, Ruth
    Mukker, Jatinder Kaur
    Enderlin, Marta
    Hicking, Christine
    Grombacher, Thomas
    Locatelli, Giuseppe
    Szucs, Zoltan
    Gounaris, Ioannis
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2024, 30 (10) : 2057 - 2067
  • [42] A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
    Gutierrez, M.
    Garralda, E.
    Calvo, E.
    van Dongen, M.
    Eskens, F. A.
    Finlay, M.
    Menas, F. Z.
    Zhu, C.
    Wu, M.
    Guillemin-Paveau, H.
    Abbadessa, G.
    Perez, R.
    Yildirim, O.
    Naing, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S646 - S647
  • [43] First-in-human phase I dose-escalation study of the oral selective C-met inhibitor EMD 1204831 in patients with advanced solid tumors.
    Amin, Hesham M.
    Falchook, Gerald Steven
    Fu, Siqing
    Hong, David S.
    Tsimberidou, Apostolia Maria
    Naing, Aung
    Wheler, Jennifer J.
    Piha-Paul, Sarina Anne
    Janku, Filip
    Klevesath, Manfred B.
    Jego, Virginie
    Johne, Andreas
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
    Yu, X.
    Zhang, J.
    Liu, R.
    Deng, Y.
    Cai, Y.
    Sun, Y.
    Dang, Q.
    Hong, W.
    Song, Z.
    Guo, S.
    Gao, S.
    Su, W.
    Shi, M.
    Fan, S.
    Zhang, B.
    Pan, B.
    Ren, Y.
    Wang, J.
    Zhong, C.
    Ma, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1496 - S1497
  • [45] A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
    Herbst, Roy S.
    Kurzrock, Razelle
    Hong, David S.
    Valdivieso, Manuel
    Hsu, Cheng-Pang
    Goyal, Lovely
    Juan, Gloria
    Hwang, Yuying C.
    Wong, Susan
    Hill, John S.
    Friberg, Greg
    LoRusso, Patricia M.
    CLINICAL CANCER RESEARCH, 2010, 16 (23) : 5883 - 5891
  • [46] First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors
    Li, Wei
    Wang, Yongsheng
    Xiong, Anwen
    Gao, Ge
    Song, Zhengbo
    Zhang, Yiping
    Huang, Dingzhi
    Ye, Feng
    Wang, Qiming
    Li, Zhihui
    Liu, Jiaye
    Xu, Chunwei
    Sun, Yinghui
    Liu, Xijie
    Zhou, Fei
    Zhou, Caicun
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [47] First-in-human (FIH) study of E7130 in patients (pts) with advanced solid tumors: Primary result of dose-escalation part
    Doi, T.
    Matsubara, N.
    Naito, Y.
    Kuboki, Y.
    Harano, K.
    Ono, M.
    Urasaki, T.
    Ohmoto, A.
    Hisai, T.
    Mikubo, A.
    Ikezawa, H.
    Shiba, S.
    Ito, K.
    Asano, O.
    Takahashi, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S608 - S609
  • [48] Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors
    Cook, Natalie
    Blagden, Sarah
    Lopez, Juanita
    Sarker, Debashis
    Greystoke, Alastair
    Haris, Noor Md
    Kazmi, Farasat
    Anam, Kaiser
    Franco, Ana Ortego
    Pihlak, Rille
    Goodwin, Louise
    Wilson, David
    Phillips, Caroline
    Robertson, Jane
    Timmis, Helen
    Tilston, Craig
    Woodcock, Simon A.
    Plummer, Ruth
    CANCER RESEARCH, 2024, 84 (07)
  • [49] First-in-Human, Dose Escalation and Expansion Study of MT-6402 in Patients With PD-L1 Expressing Advanced Solid Tumors
    Spigel, D. R.
    Anand, B.
    Carroll, K.
    Dekker, J.
    Georgy, A.
    Hankins, S.
    Rethy, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1102 - S1102
  • [50] A FIRST-IN-HUMAN STUDY OF INTRAVENOUS BAL 101553, A NOVEL MICROTUBULE INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Molife, L. Rhoda
    King, J.
    Smith, A.
    D'arcangelo, M.
    Brown, N.
    Diamantis, N.
    Lane, H.
    Hoffmann, A. H. Schmitt
    Engelhardt, M.
    Plummer, R.
    Kristeleit, R.
    ANNALS OF ONCOLOGY, 2015, 26
12345